

Notification of Suspected Gonorrhea Treatment Failure Form for LHJs

Upload this form to the CalREDIE incident's electronic filing cabinet and inform stdcb argc@cdph.ca.gov within 24 hours

A patient who resides in the local health jurisdiction (______) has been identified with a gonorrhea (GC)

infection and is suspected of having gonorrhea treatment failure. We are notifying you because after assessing this

patient we have determined reinfection is unlikely. The patient meets the following criteria for suspected treatment failure:

□ Has persistent symptoms 3-5 days despite following appropriate treatment with no sexual contact reported since treatment. Other causes of symptoms have been ruled out (e.g., chlamydia, trichomoniasis, *Mycoplasma genitalium*). For those with pharyngeal symptoms, consider testing for common etiologies such as COVID-19 and Group A Streptococcus.

□ Has a positive test of cure (TOC) and reports no sexual contact since treatment. A positive TOC is defined as the following:

- A positive culture at least 72 hours after treatment, or
- A positive nucleic acid amplification test (NAAT*) obtained:
 - More than 7 days after treatment for anogenital gonorrhea
 - More than 14 days after treatment for pharyngeal gonorrhea

□ Has a positive test of cure **and** there is evidence of decreased susceptibility to cephalosporins on

antimicrobial susceptibility testing** (regardless of reported sexual contact since treatment).

*Note: BD Probetec NAAT testing may have false-positive results due to commensal *Neisseria* species in the oropharynx. **Decreased susceptibility to ceftriaxone = MIC $\ge 0.125 \mu g/mL$ or cefixime = MIC $\ge 0.25 \mu g/mL$

Table 1. Case Information

CalREDIE ID	Last Name	First Name	Date of Birth (mm/dd/yyyy)	Weight (lbs)	Sex Assigned at Birth

Table 2. Gonorrhea Testing Information (Use a separate line for each specimen tested)

Date of Specimen Collection (mm/dd/yyyy)	Specimen Type (e.g., urethral, endocervical, pharyngeal, rectal, etc.)	Diagnostic Test (Culture vs NAAT) If NAAT, which assay platform (e.g., Aptima Combo 2 Assay)?	Result	Testing Location

Table 3. Treatment Received

Antibiotic	Dose (mg)	Route (IV, IM, PO)	Frequency (Every hours)	Duration (Days)	Date Started (mm/dd/yyyy)



Notification of Suspected Gonorrhea Treatment Failure Form for LHJs

Upload this form to the CalREDIE incident's electronic filing cabinet and inform stdcb argc@cdph.ca.gov within 24 hours

Has antibiotic susceptibility testing (AST) been performed?

🗆 Yes		
0	Date submitted:	(mm/dd/yyyy)
0	Lab:	
🗆 No		

□ Unknown

If results are available, please complete table below Antibiotic Susceptibility Testing MIC Values:

	Urethral	Pharyngeal	Rectal	Cervical
Ceftriaxone				
Cefixime				
Azithromycin				
Ciprofloxacin				
Tetracycline				
Penicillin				
Ofloxacin				
Other				

Additional Case Notes (include information on negative test results for other infections)				



Supplemental Information

Please complete the following questions for the case and submit to STD Control Branch within 5 business days:

Table 1. Case Information

CalREDIE ID	Last Name	First Name	Date of Birth (mm/dd/yyyy)	Weight (lbs)	Sex Assigned at Birth

- 1. Did they engage in oral, vaginal, or anal sex after treatment?
 - 🗆 Yes
 - 🗆 No
 - □ Unknown

2. Did they have any symptoms? (If no, skip to question 7)

- □ Yes (*if yes, answer questions 3-6*)
- 🗆 No
- □ Unknown
- 3. Date of symptom onset: _____ (mm/dd/yyyy)

4. Which symptoms (select all that apply)?

- □ Abnormal vaginal discharge
- Penile discharge
- Rectal symptoms
- □ Abnormal vaginal bleeding
- □ Testicular pain/discomfort
- \Box Sore throat
- □ Pelvic/abdominal pain
- Dysuria
- Unknown
- □ Other: _____

5. Did they experience full or partial symptom resolution after treatment?

- □ Yes
 - List symptom(s) that fully or partially resolved: ______
- 🗆 No
- □ Unknown

6. Did they experience any symptom reappearance?

- 🗌 Yes
 - List symptom(s) that reappeared: ______
- 🗆 No
- □ Unknown

7. Ethnicity:

- □ Hispanic or Latino
- □ Not Hispanic or Latino
- Unknown



Supplemental Information

8. Race (select all that apply):

- □ American Indian or Alaska Native
- □ Asian
- □ Black or African American
- □ Native Hawaiian or Other Pacific Islander
- □ White
- □ Other
- 🗆 Unknown

9. Sex Assigned at Birth:

- □ Male
- □ Female
- □ Non-binary

10. Current Gender Identity:

- □ Male
- Female
- □ Genderqueer or non-binary
- □ Trans male / Trans man
- □ Trans female / Trans woman
- Another gender (specify): _____
- Unknown

11. Are they currently pregnant?

- □ Yes
- 🗆 No
- □ N/A

12. Sexual orientation (self-reported):

- □ Heterosexual or straight
- □ Bisexual
- □ Gay, lesbian, same gender loving
- □ Questioning, unsure, patient doesn't know
- Another sexual orientation (specify): _____
- □ Unknown

13. Gender of sex partners (select all that apply):

- □ Male
- □ Female
- $\hfill\square$ Genderqueer or non-binary
- □ Trans male / Trans man
- □ Trans female / Trans woman
- Another gender (specify): ______
- 🗌 Unknown



Supplemental Information

- 14. In the past 2 months prior to symptom onset (or diagnosis, if asymptomatic), how many sexual partners have they had?
 - Number partners: _____
 - □ Unknown
- 15. In the past 2 months prior to symptom onset (or diagnosis, if asymptomatic), what type of sex have they engaged in (select all that apply)?
 - □ *Received* oral sex
 - □ *Performed* oral sex
 - □ *Insertive* vaginal sex (their penis in partner's vagina)
 - □ *Receptive* vaginal sex (partner's penis in their vagina)
 - □ *Insertive* anal sex (their penis in partner's rectum)
 - □ *Receptive* anal sex (partner's penis in their rectum)
 - □ Unknown
- 16. In the past 2 months prior to symptom onset (or diagnosis, if asymptomatic), did they have group sex or attend sex parties?
 - □ Yes
 - o If yes, list type of venue (e.g., bathhouse) & name of venue if available: _____
 - 🗌 No
 - Unknown
- 17. In the past 2 months prior to symptom onset (or diagnosis, if asymptomatic), what type of drug have they used? (Check all that apply)
 - □ Methamphetamine
 - □ Heroin
 - □ Cocaine/crack
 - □ Injection drug use
 - □ Other:
 - □ Unknown
 - □ None

18. In the past 2 months prior to symptom onset (or diagnosis, if asymptomatic), have they exchanged money/food/drugs for sex?

- □ Yes
- □ No
- □ Unknown

19. In the past 12 months prior to symptom onset (or diagnosis, if asymptomatic), have they been unhoused?

- □ Yes
- 🗆 No
- □ Unknown

20. In the past 12 months prior to symptom onset (or diagnosis, if asymptomatic), have they been incarcerated?

- □ Yes
- 🗆 No
- □ Unknown



21. In the past 2 months prior to symptom onset (or diagnosis, if asymptomatic), have they traveled outside the continental United States (including Hawaii) and had sexual partners while traveling?

	Yes	
	 List location(s) visited: 	
	No	
	Unknown	
22.	he past 2 months prior to symptom onset (or diagnosis, if asymptomatic), have they engaged in sex with	h a
	son who lives (or recently traveled) outside the continental United States (including Hawaii)?	
	Yes	
	 List location(s): 	
	No	
	Unknown	
23.	he past 2 months have they taken any antibiotics besides ones listed in Table 3 above?	
	Yes	
	 If yes, name(s) of antibiotic(s): 	
	No	
	Unknown	
24.	ve they ever tested positive for HIV?	
	Yes	

- Unknown

Note: Document all case investigation and partner services findings in case investigation notes in CalREDIE.

Upload this form to the CalREDIE incident's electronic filing cabinet and inform stdcb_argc@cdph.ca.gov within 5 business days